SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that results from
preclinical studies of ANX-510 (CoFactor(R)) in combination with
intravenous 5-fluorouracil (5-FU) and capecitabine (Xeloda(R)), an oral
prodrug of 5-FU, will be presented at the American Association for Cancer
Research (AACR) Annual Meeting in Los Angeles, CA. The abstract entitled
"Antitumor activity and safety of a hybrid treatment regimen of
5,10-methylenetetrahydrofolate, 5-fluorouracil, and capecitabine in a
colorectal tumor xenograft model" will be presented on Tuesday, April 17 at
1:00 p.m. local time.
About CoFactor
CoFactor (ANX-510) is a folate-based biomodulator drug designed to
replace leucovorin as the preferred method to enhance the activity and
reduce associated toxicity of the widely used cancer chemotherapy
5-fluorouracil (5-FU). In comparison to leucovorin, CoFactor creates more
stable binding of the active form of 5-FU to the target enzyme, thymidylate
synthase (TS). CoFactor bypasses the metabolic pathway required by
leucovorin to deliver the active form of folate, allowing 5-FU to work more
effectively. CoFactor is in Phase 3 and Phase 2b clinical trials for the
treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical
trial for the treatment of advanced breast cancer.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The potential
risks and uncertainties that could cause actual results for our CoFactor
studies to differ materially include, but are not limited to: the validity
of research results; uncertainties inherent in the drug development
process; the timing and success of clinical trials; the receipt of
necessary approvals from the FDA and other regulatory agencies; and other
risks and uncertainties more fully described in ADVENTRX's press releases
and public filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov. ADVENTRX does not intend to update any forward-looking
statement, including as set forth in this press release, to reflect events
or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/gh/cnoc/comp/920134.html/
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866; or Amy Martini of WeissComm
Partners, +1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc.
|
